regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Heart disease === Tricuspid regurgitation is usually secondary to right ventricular dilation which may be due to left ventricular failure (the most common cause), right ventricular infarction, inferior myocardial infarction, or cor pulmonale Other causes of tricuspid regurgitation include carcinoid syndrome and myxomatous degeneration.
== History == Bovine pancreatic ribonuclease became a common model system in the study of proteins largely because it was extremely stable and could be purified in large quantities. In the 1940s Armour and Company purified a kilogram of protein - a very large quantity, particularly by the protein purification standards of the time - and offered samples at low cost to interested scientists. The ability to have a single lot of purified enzyme made it a predominant model system for protein studies. It remains commonly referred to as ribonuclease A or RNase A as the most prominent member of its protein family, known variously as pancreatic ribonuclease, ribonuclease A, or ribonuclease I. Christian Anfinsen's studies of the oxidative folding process of bovine pancreatic ribonuclease laid the groundwork for understanding the relationship between amino acid sequence and a protein's folded three-dimensional structure and solidified the thermodynamic hypothesis of protein folding, according to which the folded form of a protein represents its free energy minimum. RNase A was the first enzyme for which a correct catalytic mechanism was proposed, even before its structure was known. RNase A was the first protein for showing the effects of non-native isomers of peptide bonds preceding proline residues in protein folding.
This decrease is almost unnoticeable if a smooth aneurysm is produced in the wall of a capillary by heating and pressurization, as plug flow can be preserved. This invention by Gary Gordon, US Patent 5061361, typically triples the absorbance path length. When used with a UV absorbance detector, the wider cross-section of the analyte in the cell allows for an illuminating beam twice as large, which reduces shot noise by a factor of two. Together these two factors increase the sensitivity of Agilent Technologies's Bubble Cell CE Detector six times over that of one using a straight capillary. This cell and its manufacture are described on page 62 of the June 1995 issue of the Hewlett-Packard Journal.
=== Cosmetics === Some sucrose esters, such as sucrose distearate, sucrose dilaurate, sucrose palmitate, etc. are added in cosmetics products as an emulsifier. Some have a function in skin conditioning and emollient. Cosmetics products that might have sucrose esters as an ingredient includes eyelash products, hair treatments, oil gels, skin products and deodorants.
Sources: en.wikipedia.org
== Economic significance == In 2024, South Africa's logistics sector contributed R518.4 billion towards the country's GDP, a year-over-year increase of 4.3%. South Africa's logistics sector is expected to grow at a CAGR of 9.1% from 2026 to 2033. In 2025, the country accounted for 2.3% of the global logistics market. In 2026, South Africa's logistics sector was growing the fastest out of all countries in the Middle East & Africa region. Examples from Wesgro of the South African logistics sector's impact on the country's economy as a whole are in the table below.
Invented in 1888 by Max Ams, modern double seams provide an airtight seal to a can. This airtight nature is crucial to keeping micro-organisms out of the can and keeping the can's contents sealed inside. Thus, double seamed cans are also known as Sanitary Cans. Developed in 1900 in Europe, this sort of can was made of the traditional cylindrical body made with tin plate. The two ends (lids) were attached using what is now called a double seam. A can thus sealed is impervious to contamination by creating two tight continuous folds between the can's cylindrical body and the lids. This eliminated the need for solder and allowed improvements in manufacturing speed, reducing cost. Double seaming uses rollers to shape the can, lid and the final double seam. To make a sanitary can and lid suitable for double seaming, manufacture begins with a sheet of coated tin plate. To create the can body, rectangles are cut and curled around a die, and welded together creating a cylinder with a side seam. Rollers are then used to flare out one or both ends of the cylinder to create a quarter circle flange around the circumference. Precision is required to ensure that the welded sides are perfectly aligned, as any misalignment will cause inconsistent flange shape, compromising its integrity. A circle is then cut from the sheet using a die cutter. The circle is shaped in a stamping press to create a downward countersink to fit snugly into the can body. The result can be compared to an upside down and very flat top hat.
The development of the chemistry of alkaloids was accelerated by the emergence of spectroscopic and chromatographic methods in the 20th century, so that by 2008 more than 12,000 alkaloids had been identified. The first complete synthesis of an alkaloid was achieved in 1886 by the German chemist Albert Ladenburg. He produced coniine by reacting 2-methylpyridine with acetaldehyde and reducing the resulting 2-propenyl pyridine with sodium.
The female is gravid for 50 to 59 days. The king cobra is the only snake that builds a nest using dry leaf litter, starting from late March to late May. Most nests are located at the base of trees, are up to 55 cm (22 in) high in the centre and 140 cm (55 in) wide at the base. They consist of several layers and have mostly one chamber, into which the female lays eggs. Clutch size ranges from 7 to 43 eggs, with 6 to 38 eggs hatching after incubation periods of 66 to 105 days. Temperature inside nests is not steady but varies depending on elevation from 13.5 to 37.4 °C (56.3 to 99.3 °F). Females stay by their nests between two and 77 days. Hatchlings are between 37.5 and 58.5 cm (14.8 and 23.0 in) long and weigh 9 to 38 g (0.32 to 1.34 oz). The king cobra was shown to be capable of facultative parthenogenesis. The parthenogenetic mechanism appears to be a variation of meiosis referred to as terminal fusion automixis in which there is fusion of the meiotic products formed at the anaphase II stage of meiosis. The venom of hatchlings is as potent as that of the adults. They may be brightly marked, but these colours often fade as they mature. They are alert and nervous, being highly aggressive if disturbed. The average lifespan of a wild king cobra is about 20 years.
Healthy diet (a diet with limited refined carbohydrates, added sugars, trans fats, as well as limited intake of sodium and total calories) Physical fitness (30–45 minutes of cardiovascular exercise per day, 3–5 days a week) Weight loss by as little as 5–10 percent may have a significant impact on overall health
Sources: en.wikipedia.org
== N == NAT – National Cancer Institute (NCI) – National Institute of Allergy and Infectious Diseases (NIAID) – National Institute of Child Health and Human Development (NICHD) – National Institutes of Health (NIH) – National Library of Medicine (NLM) – National Prevention Information Network (NPIN) – natural history study – natural killer cells (NK cells) – NCI – New Drug Application – nebulized – Nef – neoplasm – nephrotoxic – neuralgia – neurological complications of AIDS – neuropathy – neutralization – neutralizing antibody – neutralizing domain – neutropenia – neutrophil – New Drug Application (NDA) – New York Cares – NIAID – NICHD – night sweat – NIH – NK cell – NLM – NNRTI – non-Hodgkin's lymphoma (NHL) – non-nucleoside reverse transcriptase inhibitors (NNRTI) – non-steroidal anti-inflammatory drugs (NSAID) – NRTI – nucleic acid – nucleic acid test – nucleocapsid – nucleoli – nucleoside – nucleoside analog – nucleoside reverse transcriptase inhibitors (NRTI) – nucleotide – nucleotide analogs – nucleus – null cell
==== Fowler process ==== A major breakthrough that allowed the large scale manufacture of fluorocarbons was the Fowler process. In this process, cobalt trifluoride is used as the source of fluorine. Illustrative is the synthesis of perfluorohexane:
=== Other work === In 1905, Thomson discovered the natural radioactivity of potassium. In 1906, Thomson demonstrated that hydrogen had only a single electron per atom. Previous theories allowed various numbers of electrons. From 1916 to 1918, Thomson chaired the "Committee appointed by the Prime Minister to enquire into the Position of Natural Science in the Educational System of Great Britain". The Report of the Committee, published in 1918, was known as the Thomson Report.
Shipping experts optimize their service and costs by sampling rates from several carriers, brokers and online marketplaces. When obtaining rates from different providers, shippers may find a wide range in the pricing offered. If a shipper in the United States uses a broker, freight forwarder or another transportation intermediary, it is common for the shipper to receive a copy of the carrier's Federal Operating Authority. Freight brokers and intermediaries are also required by Federal Law to be licensed by the Federal Highway Administration. Experienced shippers avoid unlicensed brokers and forwarders because if brokers are working outside the law by not having a Federal Operating License, the shipper has no protection in case of a problem. Also, shippers typically ask for a copy of the broker's insurance certificate and any specific insurance that applies to the shipment. Overall, shipping costs have fallen over the past decades. A further drop in shipping costs in the future might be realized through the application of improved 3D printing technologies.
=== March === March 28, 2013: Cyprus Banks in Cyprus re-open after having been closed for two weeks. The government of Cyprus agrees a 10 billion euro bailout deal with the EU and IMF. Depositors with more than € 100,000 in certain banks will lose up to 60% of their deposits. An earlier proposal that would have seen depositors with less than €100,000 losing 6.75% of their deposits fails to attract a single vote in favor in the Cypriot parliament. Russia is expected to help finance the bailout by delaying the repayment of a 2.5 billion euro loan to Cyprus until 2021.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.